Trial reportWomen's health (London, England)2016
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
Trial report in Women's health (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01382719 (A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder)
Who cites it
28 citing papers in PubMed, 99 citations in OpenAlex.
- Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder.The Journal of clinical investigation · 2022Trial
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019Trial
- Multilevel analyses of on-demand medication data, with an application to the treatment of Female Sexual Interest/Arousal Disorder.PloS one · 2019Trial
- Neural Melanocortin Receptors in Fish: Insights into Growth Regulation and Aquaculture Advancement.Biomolecules · 2026Review
- Translation and investigation of the psychometric properties of the revised female sexual distress scale among Iranian couples.Scientific reports · 2025Article
- Review
- What Women Want? The State of the Art regarding the Treatment of Young Women with Hypoactive Sexual Desire Disorder.Pharmacology · 2024Review
- Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions.Journal of neurology · 2023Review
- Melanocortin 4 receptor signaling in Sim1 neurons permits sexual receptivity in female mice.Frontiers in endocrinology · 2023Article
- Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin.Biomolecules · 2022Review
- MC4R biased signalling and the conformational basis of biological function selections.Journal of cellular and molecular medicine · 2022Review
- Management of Hypertension with Female Sexual Dysfunction.Medicina (Kaunas, Lithuania) · 2022Review
- Melanocortin-4 receptor complexity in energy homeostasis,obesity and drug development strategies.Diabetes, obesity & metabolism · 2022Review
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire.Neurology international · 2022Review
- Psychometric validation of the Female Sexual Distress Scale-Desire/Arousal/Orgasm.Journal of patient-reported outcomes · 2021Article
- The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.Molecular metabolism · 2021Review
- Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder.Journal of patient-reported outcomes · 2020Article
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.Obstetrics and gynecology · 2019Article
- Sexual Health in Menopause.Medicina (Kaunas, Lithuania) · 2019Review
- Bremelanotide: First Approval.Drugs · 2019Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimEvaluate efficacy/safety of bremelanotide (BMT), a melanocortin-receptor-4 agonist, to treat female sexual dysfunctions in premenopausal women.
methodsPatients randomized to receive placebo or BMT 0.75, 1.25 or 1.75 mg self-administered subcutaneously, as desired, over 12 weeks. Primary end point was change in satisfying sexual events/month. Secondary end points included total score changes on female sexual function index and female sexual distress scale-desire/arousal/orgasm.
resultsEfficacy data, n = 327. For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), -11.1 versus -6.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014). Adverse events: nausea, flushing, headache.
conclusionIn premenopausal women with female sexual dysfunctions, self-administered, as desired, subcutaneous BMT was safe, effective, and well tolerated (NCT01382719).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.